Executive Summary
CGI Federal Inc., a Timken Company subsidiary, secured a $108M GSA delivery order for EPA IT enterprise development, with potential expansion to $523M via options through 2030. This bullish signal provides multi-year revenue visibility in government IT services, though realization hinges on performance-based options and award fees.
No outlays yet signal early-stage execution, warranting monitoring for margin impacts from $15M subawards.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Contract Option Exercises digest from March 27, 2026.
Investment Signals (1)
- GSA awards $108M EPA IT order with $523M potential (HIGH)▲
Cost-plus award fee contract obligated $108M, base + options value $523M for computer systems design through 2030.
Risk Flags (2)
- Execution [MEDIUM RISK]▼
Options may not exercise beyond 2026 end date; award fees tied to performance evaluations.
- Competitive [LOW RISK]▼
$15M subawards to 47 recipients could pressure margins.
Opportunities (2)
- ◆
Full exercise of options to unlock $523M total value by 2030.
- ◆
Expansion via additional GSA FAS FEDSIM task orders in EPA IT support.
Sector Themes (1)
- ◆
GSA full-and-open competition awards large cost-plus contracts for EPA enterprise IT development.
Watch List (1)
- 👁
{"entity"=>"CGI Federal EPA IT Contract (47QFCA23F0030)", "reason"=>"Potential $415M upside from options; no outlays yet indicate execution phase.", "trigger"=>"option exercises or outlay starts >$10M"}
Get daily alerts with 1 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Contract Option Exercises
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals